These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24322877)

  • 1. Target-mediated drug disposition model and its approximations for antibody-drug conjugates.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):35-47. PubMed ID: 24322877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
    Bender B; Leipold DD; Xu K; Shen BQ; Tibbitts J; Friberg LE
    AAPS J; 2014 Sep; 16(5):994-1008. PubMed ID: 24917179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer.
    Lu D; Joshi A; Wang B; Olsen S; Yi JH; Krop IE; Burris HA; Girish S
    Clin Pharmacokinet; 2013 Aug; 52(8):657-72. PubMed ID: 23553425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates.
    Wada R; Erickson HK; Lewis Phillips GD; Provenzano CA; Leipold DD; Mai E; Johnson H; Tibbitts J
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):969-80. PubMed ID: 25186956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).
    Singh AP; Maass KF; Betts AM; Wittrup KD; Kulkarni C; King LE; Khot A; Shah DK
    AAPS J; 2016 Jul; 18(4):861-75. PubMed ID: 27029797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.
    Marcoux J; Champion T; Colas O; Wagner-Rousset E; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
    Protein Sci; 2015 Aug; 24(8):1210-23. PubMed ID: 25694334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.
    Erickson HK; Lewis Phillips GD; Leipold DD; Provenzano CA; Mai E; Johnson HA; Gunter B; Audette CA; Gupta M; Pinkas J; Tibbitts J
    Mol Cancer Ther; 2012 May; 11(5):1133-42. PubMed ID: 22408268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADME of antibody-maytansinoid conjugates.
    Erickson HK; Lambert JM
    AAPS J; 2012 Dec; 14(4):799-805. PubMed ID: 22875610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.
    Haddish-Berhane N; Shah DK; Ma D; Leal M; Gerber HP; Sapra P; Barton HA; Betts AM
    J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):557-71. PubMed ID: 23933716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer.
    Chudasama VL; Schaedeli Stark F; Harrold JM; Tibbitts J; Girish SR; Gupta M; Frey N; Mager DE
    Clin Pharmacol Ther; 2012 Oct; 92(4):520-7. PubMed ID: 22968044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
    Khot A; Tibbitts J; Rock D; Shah DK
    AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
    Sapra P; Betts A; Boni J
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):541-55. PubMed ID: 23978126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).
    Singh AP; Shah DK
    AAPS J; 2017 Jul; 19(4):1054-1070. PubMed ID: 28374319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.
    Dere R; Yi JH; Lei C; Saad OM; Huang C; Li Y; Baudys J; Kaur S
    Bioanalysis; 2013 May; 5(9):1025-40. PubMed ID: 23641694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice.
    Jumbe NL; Xin Y; Leipold DD; Crocker L; Dugger D; Mai E; Sliwkowski MX; Fielder PJ; Tibbitts J
    J Pharmacokinet Pharmacodyn; 2010 Jun; 37(3):221-42. PubMed ID: 20424896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.
    Gibiansky L; Gibiansky E
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):803-12. PubMed ID: 19505189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approximations of the target-mediated drug disposition model and identifiability of model parameters.
    Gibiansky L; Gibiansky E; Kakkar T; Ma P
    J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):573-91. PubMed ID: 19005743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy.
    Cilliers C; Guo H; Liao J; Christodolu N; Thurber GM
    AAPS J; 2016 Sep; 18(5):1117-1130. PubMed ID: 27287046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats.
    Shen BQ; Bumbaca D; Yue Q; Saad O; Tibbitts J; Khojasteh SC; Girish S
    Drug Metab Lett; 2015; 9(2):119-31. PubMed ID: 26031461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.